This article is more than 5 years old. Information may no longer be current.
Bioventus acquires international assets for Gladerma’s OA treatment
Click Here to Manage Email Alerts
Bioventus announced that it has entered into an agreement with Galderma to acquire the international assets for Durolane, a product that helps osteoarthritis pain in a variety of joints.
According to a company press release, Bioventus previously had exclusive global distribution rights and served as the distributor for Durolane in Europe, Canada and Australia. With the new agreement, Galderma will continue to serve as the manufacturer of Durolane; however, Bioventus now controls all future plans and distribution for the product outside of the United States.
“Durolane has been an invaluable product to numerous [osteoarthritis] OA sufferers throughout the world,” Anthony Bihl, chief executive officers of Bioventus, stated in the release. “We see growth potential and new market opportunities for the product, and determined that controlling the assets puts us in the best position to realize these opportunities.”